Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intravenous Conivaptan

Intravenous Conivaptan Am J Cardiovasc Drugs 2008; 8 (5): 349 GUEST COMMENTARIES 1175-3277/08/0005-0349/$48.00/0 © 2008 Adis Data Information BV. All rights reserved. Conivaptan is one of a family of new agents that directly and effectively antagonize the V receptors (the renal receptor that A viewpoint by Steven R. Goldsmith 2 mediates the effect of arginine vasopressin to retain water). Recent Department of Medicine, University of Minnesota, data from clinical trials indicate that conivaptan is highly effective Minneapolis, Minnesota, USA compared with placebo in correcting hyponatremia in patients Hyponatremia is an extremely common electrolyte disorder. It with either normal or expanded blood volume. Conivaptan also is associated with poor clinical outcomes, perhaps most partic- blocks the effects of arginine vasopressin at the V receptor (the 1A ularly in patients with congestive heart failure (CHF). Severe receptor on blood vessels, platelets, and myocardium). For the hyponatremia may be life-threatening, but even mild or moderate patient with CHF, relief of vasoconstriction by blocking the V 1A hyponatremia may be associated with significant neurocognitive receptor would potentially be an additional benefit, but clinical deficits. Hyponatremia may be associated with volume depleted data in CHF patients without hyponatremia are limited at this time. states, but is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Intravenous Conivaptan

Download PDF
1 page

Intravenous Conivaptan

Abstract

Am J Cardiovasc Drugs 2008; 8 (5): 349 GUEST COMMENTARIES 1175-3277/08/0005-0349/$48.00/0 © 2008 Adis Data Information BV. All rights reserved. Conivaptan is one of a family of new agents that directly and effectively antagonize the V receptors (the renal receptor that A viewpoint by Steven R. Goldsmith 2 mediates the effect of arginine vasopressin to retain water). Recent Department of Medicine, University of Minnesota, data from clinical trials indicate that conivaptan is highly...
Loading next page...
 
/lp/springer-journals/intravenous-conivaptan-fsc0rJWJWb

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2008 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200808050-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2008; 8 (5): 349 GUEST COMMENTARIES 1175-3277/08/0005-0349/$48.00/0 © 2008 Adis Data Information BV. All rights reserved. Conivaptan is one of a family of new agents that directly and effectively antagonize the V receptors (the renal receptor that A viewpoint by Steven R. Goldsmith 2 mediates the effect of arginine vasopressin to retain water). Recent Department of Medicine, University of Minnesota, data from clinical trials indicate that conivaptan is highly effective Minneapolis, Minnesota, USA compared with placebo in correcting hyponatremia in patients Hyponatremia is an extremely common electrolyte disorder. It with either normal or expanded blood volume. Conivaptan also is associated with poor clinical outcomes, perhaps most partic- blocks the effects of arginine vasopressin at the V receptor (the 1A ularly in patients with congestive heart failure (CHF). Severe receptor on blood vessels, platelets, and myocardium). For the hyponatremia may be life-threatening, but even mild or moderate patient with CHF, relief of vasoconstriction by blocking the V 1A hyponatremia may be associated with significant neurocognitive receptor would potentially be an additional benefit, but clinical deficits. Hyponatremia may be associated with volume depleted data in CHF patients without hyponatremia are limited at this time. states, but is

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Aug 17, 2012

There are no references for this article.